Abstract 82MO
Background
The European Reference Network for Rare Adult Cancers (EURACAN) G2 domain deals with rare gynaecological cancers. Within this domain, virtual multi-disciplinary tumor boards (MDTs) were implemented to advise on clinical management of complex cases. Here, we present the 6-year activity outcomes.
Methods
EURACAN G2 MDTs were organized monthly since November 2017 by Karolinska University Hospital, Stockholm. From March 2021 to March 2023, the MDTs were coordinated by Ospedale San Raffaele, Milan and since April 2023 by Hospital Clinico San Carlos, Madrid. A summary of cases was circulated to participants prior to MDTs and recommendations were distributed following each MDT. Background data and outcomes were registered prospectively. Follow up data were collected until March 2024.
Results
Between November 2017 and October 2023, 67 MDTs were held with participants from 18 countries and 20 centers. 260 patients were discussed (median 4 patients/session, range 1-12). Background data are shown in the table. The number of annual cases discussed has increased over time (+182% from 2017 to 2022), as is the median number of participants (+27% from 2020 to 2022). The MDTs resulted in a recommendation for pathological review and genetic sequencing in 24% and 9.6% of cases. Surveillance was recommended for 17% of cases. Alternative treatment opportunities were suggested for 58.7% of patients compared to the initial proposed management. Follow up data were available for 155 patients. Adherence to treatment recommendation was 94%. As a consequence of MDT recommendations, access to off-label therapies was achieved in 37 patients (23.8%) and 4 patients (2.5%) were enrolled in clinical trials abroad. Table: 82MO
| Patients N=260 | |
| DIAGNOSIS | |
| Gestational trophoblastic disease | 51 (19.6%) |
| Malignant ovarian germ cell tumors | 51 (19.6%) |
| Sex cord stromal tumors | 38 (14.6%) |
| Other Rare ovarian histologies | 76 (29.2%) |
| Rare uterine tumors | 20 (7.8%) |
| Rare cervical tumors | 11 (4.2%) |
| Other | 13 (5%) |
| PREVIOUS LINES OF TREATMENT (median, range) | 1 (0-10) |
| INDICATIONS FOR DISCUSSION* | |
| Initial management | 117 (42.5%) |
| Relapse/disease Progression | 133 (48.4%) |
| Other (follow up, further investigation) | 25 (9.1%) |
* N= 275 case discussions.
Conclusions
EURACAN G2 domain MDTs increasingly offer opportunity for clinical support and access to treatment alternatives for patients with complex rare gynecological cancers.
Legal entity responsible for the study
EURACAN G2 network.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35MO - Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Presenter: Maria Pilar Barretina Ginesta
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
36MO - Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Presenter: Yeh Chen Lee
Session: Mini Oral session 1
Resources:
Abstract
37MO - Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups
Presenter: Robert Coleman
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
38MO - Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
Presenter: Mansoor Raza Mirza
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
39MO - Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer
Presenter: Sandro Pignata
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
40MO - First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status
Presenter: Els Van Nieuwenhuysen
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 35MO+36MO, 37MO, 38MO, 39MO and 40MO
Presenter: Ramez Eskander
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
45MO - Management of stage I ovarian Sertoli-Leydig cell tumors: Prognostic factors from a multicenter international retrospective study
Presenter: Giovanna Scarfone
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 82MO and 45MO
Presenter: Jubilee Brown
Session: Mini Oral session 1
Resources:
Slides
Webcast